U.S. – Page 2 – Talk Bio

AstraZeneca Plans Direct US Stock Listing While Maintaining UK Headquarters

3 months ago talkbio0Tagged American Depositary Receipts, AstraZeneca, Capital Markets, Drug Industry, headquarters, London, Nasdaq Stockholm, NYSE, shareholders, Stock exchange, U.S., UK

AstraZeneca; US stock listing; NYSE; London Stock Exchange; Nasdaq Stockholm; American Depositary Receipts; capital markets; pharmaceutical industry; shareholders; UK headquarters

Bristol Myers Squibb to Launch Schizophrenia Drug Cobenfy in UK at US Price

3 months ago talkbio0Tagged Antipsychotic Agents, Cholinergic Receptors, Cobenfy, drug price, launch, Myers, Nance-Horan syndrome, Prices, Schizophrenia, squibb, U.S., UK

Bristol Myers Squibb; Cobenfy; schizophrenia; UK launch; drug pricing; US list price; NHS; cholinergic receptors; antipsychotic; 2026

AbbVie Extends Rinvoq Exclusivity to 2037, Delaying Generics in U.S.

3 months ago talkbio0Tagged AbbVie, exclusivity extension, Generic competition, Market, Patent Settlement, pharmaceutical litigation, Rinvoq, U.S., upadacitinib

AbbVie; Rinvoq; patent settlement; generic competition; exclusivity extension; upadacitinib; US market; pharmaceutical litigation

Japan Wins Exemption for Generics in US-Japan Trade Deal

3 months ago talkbio0Tagged generic pharmaceuticals, Japan, semiconductor supply chains, tariff exemption, TNFRSF19 gene, Transplant Registry Unified Management Program, U.S.

Japan; US Trade Deal; generic pharmaceuticals; tariff exemption; semiconductor supply chains; Trump administration

Johnson & Johnson Commits $2B to Fujifilm North Carolina Site in Latest US Manufacturing Push

4 months ago talkbio0Tagged Billion, Biopharma, Fujifilm, Investments, Johnson and Johnson, Manufacturing, North Carolina, Surgical construction, U.S.

Johnson & Johnson; Fujifilm; manufacturing; North Carolina; $2 billion investment; biopharma; job creation; US manufacturing

GSK set to receive over $500M from mRNA patent settlement tied to BioNTech–CureVac–Pfizer deal

4 months ago talkbio0Tagged BioNTech, BioNTech acquisition, COVID19 (disease), CureVac, global framework, Influenza virus vaccine, Licensing, Litigation, Pfizer, RNA, Messenger, royalties, settlement, SmithKline Beecham, U.S., upfront payment, Vaccines, Vaccines, Combined

GSK; CureVac; BioNTech; Pfizer; mRNA patents; settlement; royalties; COVID-19 vaccine; influenza vaccine; combination vaccines; licensing; upfront payment; US litigation; global framework; BioNTech acquisition of CureVac

Amid MFN Talks, Lilly Chief Warns US Adoption of International Drug Prices Could Bring ‘Worst of Two Worlds’

4 months ago talkbio0Tagged Cautionary Warning, Chief, Does speak, Drug Industry, drug price, Eli Lilly, International Drug Prices, MFN, Policy, U.S.

Lilly chief; MFN talks; international drug prices; US drug pricing; pharmaceutical industry; policy warning

Trump’s Pharmaceutical Tariffs Materialize in New US-EU Trade Deal

5 months ago talkbio0Tagged 15%, European (ethnic group), Evaluation, pharmaceutical tariffs, Sectioning technique, tariff, trade agreement, Transplant Registry Unified Management Program, U.S., Union, US-EU

Trump; pharmaceutical tariffs; US-EU trade deal; 15% tariff; Section 232 investigation; European Union exports; trade agreement

Adaptimmune Expects To Cut 62% of Staff After Cell Therapy Asset Sale

5 months ago talkbio0Tagged Adaptimmune, Afami-cel, biotech workforce, cell therapy sale, layoffs, restructuring, Tecelra, U.S., WorldMeds

Adaptimmune; layoffs; cell therapy sale; US WorldMeds; restructuring; biotech workforce reduction; TECELRA; lete-cel; afami-cel; uza-cel

Trump Threatens 200% Tariffs on Pharma Imports, Proposes 1-Year Grace Period for Onshoring

5 months ago talkbio0Tagged 200, Biopharma, drug imports, grace, Investments, Menstruation, onshoring, Pharma, pharmaceutical tariffs, Policy, tariff, Transplant Registry Unified Management Program, U.S.

Trump; pharmaceutical tariffs; 200% tariff; grace period; pharma manufacturing; drug imports; US supply chain; onshoring; policy; biopharma investments